Trading Signals: HTBX Stock Price Prediction and Forecast (Mon. Dec. 28, 2015 - Mon. May. 2, 2022)(Heat Biologics, Inc.)
| HTBX latest price $3.0600 (-0.97%) ($3.0200 - $3.2450) on Thu. Mar. 31, 2022. | |
| | Trend Analysis and Forecast | | | Average Daily Percentage Swing | 5.35% (three month average) | RSI | 70 | Latest Price | $3.0600(-0.97%) | Stocks Behave Similarly | Similar Stock List | Daily Trend | HTBX declines -0.3% a day on average for past five trading days. | Weekly Trend | HTBX advances 14.3% a week on average for past two weeks. | Market Behavior | Broad based sell-off for large cap. Broad based sell-off for small cap. | Correlated ETFs | Broad market will support HTBX advance at 0% a week (0% probability) VWO(45%) EWY(42%) MCHI(40%) QQQ(39%) KWEB(37%) | Factors Impacting HTBX price | HTBX will decline at least -2.675% in a week (0% probabilities). UUP(-14%) BNDX(-7%) TIP(0%) TBT(2%) SHY(2%) | | | | | Relative Volatility | | | | Market Trend Strength | -2.675% (StdDev 5.35%) | Hourly BBV | -1.5 () | Intraday Trend | 0.3% | | | |
|
5 Day Moving Average | $3.05(0.33%) | 10 Day Moving Average | $2.99(2.34%) | 20 Day Moving Average | $2.67(14.61%) | To recent high | -13.6% | To recent low | 45.7% | Market Cap | $337m | | | | Heat Biologics, Inc. is a clinical stage company, which engages in the development of immunotherapies designed to activate and expand a patient's T-cell mediated immune system against cancer. The company's T-cell activating platform (TCAP) produces therapies designed to turn immunologically cold tumors to hot, and be administered in combination with checkpoint inhibitors and other immuno-modulators to increase clinical effectiveness. Its TCAP product candidates from the company's ImPACT and ComPACT platforms are produced from allogeneic cell lines expressing tumor-specific proteins common among cancers. The company was founded by Jeffrey Alan Wolf on June 10, 2008 and is headquartered in Morrisville, NC. |